AllianceBernstein’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-3,512,570
| Closed | -$43.7M | – | 3083 |
|
|
2016
Q4 | $43.7M | Buy |
3,512,570
+582,534
| +20% | +$7.02M | 0.04% | 492 |
|
|
2016
Q3 | $40.1M | Buy |
2,930,036
+2,453,451
| +515% | +$24.6M | 0.03% | 510 |
|
|
2016
Q2 | $3.52M | Buy |
476,585
+134,400
| +39% | +$1.01M | ﹤0.01% | 1252 |
|
|
2016
Q1 | $2.19M | Buy |
342,185
+32,400
| +10% | +$182K | ﹤0.01% | 1542 |
|
|
2015
Q4 | $1.94M | Hold |
309,785
| – | – | ﹤0.01% | 1648 |
|
|
2015
Q3 | $1.81M | Sell |
309,785
-370
| -0.1% | -$2.85K | ﹤0.01% | 1729 |
|
|
2015
Q2 | $2.56M | Hold |
310,155
| – | – | ﹤0.01% | 1584 |
|
|
2015
Q1 | $2.56M | Hold |
310,155
| – | – | ﹤0.01% | 1552 |
|
|
2014
Q4 | $2.13M | Hold |
310,155
| – | – | ﹤0.01% | 1713 |
|
|
2014
Q3 | $1.68M | Hold |
310,155
| – | – | ﹤0.01% | 1851 |
|
|
2014
Q2 | $1.98M | Buy |
310,155
+196,399
| +173% | +$1.35M | ﹤0.01% | 1783 |
|
|
2014
Q1 | $917K | Buy |
113,756
+10,989
| +11% | +$85.6K | ﹤0.01% | 2204 |
|
|
2013
Q4 | $701K | Sell |
102,767
-179,772
| -64% | -$971K | ﹤0.01% | 2311 |
|
|
2013
Q3 | $5.2M | Buy |
282,539
+14,729
| +5% | +$286K | 0.01% | 1044 |
|
|
2013
Q2 | $4.68M | Buy |
+267,810
| New | +$4.75M | 0.01% | 1046 |
|
Other funds holding ARIA
AllianceBernstein's ARIA Position: Q1 2017 in Review
AllianceBernstein sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 3,512,570 shares — an estimated $43.7M sold.
AllianceBernstein first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $43.7M in Q4 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- AllianceBernstein reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- AllianceBernstein sold 3,512,570 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $43.7M.
- AllianceBernstein first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- AllianceBernstein's Ariad Pharmaceuticals Inc position peaked at $43.7M in Q4 2016.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on AllianceBernstein's 13F filing for Q1 2017, filed 11 May 2017.